NDMA urges benzoyl peroxide warning delay until completion of photocarcinogenicity study.
This article was originally published in The Rose Sheet
Executive Summary
NDMA QUESTIONS SCIENTIFIC BASIS FOR BENZOYL PEROXIDE SUN EXPOSURE WARNING in July 17 comments to FDA. Responding to FDA's proposal to require a warning to avoid "unnecessary sun exposure" on products containing benzoyl peroxide ("The Rose Sheet" Feb. 20, p. 12), the Nonprescription Drug Manufacturers Association asserted that the warning is "not supported by scientific evidence" and should be considered "only after the NDMA-sponsored photocarcinogenicity studies that FDA requested have been completed."